Diverse Options in Influenza Prevention and Control: How to Ensure Drug Quality

Influenza is distinct from the common cold. It is an acute respiratory infectious disease caused by the influenza virus, which can lead to severe complications such as pneumonia and myocarditis, and may even be life-threatening. In recent years, influenza outbreaks have been frequent in China, particularly during the spring and autumn seasons. As the influenza virus mutates annually, the overall susceptible population continues to grow, driving an increasing demand for influenza medications.

Drugs with anti-influenza virus activity are crucial for treating and controlling influenza. Based on their mechanisms of action, antiviral drugs are primarily categorized into three classes: neuraminidase inhibitors (e.g., Oseltamivir, Peramivir, Zanamivir), hemagglutinin inhibitors (e.g., Arbidol), and RNA polymerase inhibitors (e.g., Baloxavir marboxil, Favipiravir).

As a classic antiviral, Oseltamivir continues to dominate the influenza market, with several generic versions also available in China. Baloxavir marboxil, a cap-dependent endonuclease inhibitor, represents the first novel mechanism-of-action anti-influenza drug approved by the FDA in nearly two decades. It is effective against both influenza A and B viruses. Furthermore, several domestically developed anti-influenza drugs have recently received approval.

These include Masilloxacin Tablets , China‘s first self-developed anti-influenza drug targeting the polymerase acidic (PA) protein; Andesvir Tablets , the world‘s first innovative drug targeting the PB2 subunit of the influenza A virus RNA polymerase; and Maxiloxacin Tablets , which features a novel mechanism. The introduction of these domestic innovations provides more options for clinical treatment.

As the flu season persists, drug quality control becomes a critical link in ensuring public medication safety. Drug impurity reference standards, serving as the "benchmark" in drug quality research, play an indispensable role in guaranteeing the safety and efficacy of anti-influenza drugs.

SZEB supplies related drug impurity reference standards, including Oseltamivir impurities and Baloxavir marboxil impurities, offering professional support for pharmaceutical companies in impurity research. For more details, please visit our official website: www.ex-biotech.cn .